Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20822360 | 1.00 | NT5E (1.00) | NT5E | |
| SCHEMBL24078931 | 0.94 | NT5E (0.89) | NT5E | |
| SCHEMBL24078929 | 0.94 | NT5E (0.89) | NT5E | |
| SCHEMBL24078862 | 0.93 | NT5E (0.87) | NT5E | |
| SCHEMBL19349806 | 0.93 | NT5E (0.86) | NT5E | |
| SCHEMBL20822361 | 0.93 | NT5E (0.86) | NT5E | |
| SCHEMBL19100684 | 0.93 | NT5E (0.86) | NT5E | |
| SCHEMBL24452544 | 0.92 | NT5E (0.85) | NT5E | |
| SCHEMBL24452555 | 0.92 | NT5E (0.85) | NT5E | |
| SCHEMBL22206591 | 0.90 | NT5E (0.81) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12433836-B2 | Parenterally administered immune enhancing drugs | ARCUS BIOSCIENCES, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240352057-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2024-10-24 | — | — | US | disclosed |
| EP-4306525-A2 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306525-A2 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3399984-B1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3399984-B1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| WO-2019173682-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352057-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885 |
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | NT5E 10/4885 |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885 |
| US-12433836-B2 | Parenterally administered immune enhancing drugs | NT5C2, ADA, ENTPD1 | NT5E 10/4885 |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885 |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885 |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885 |
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | NTPCR, NT5C2, NT5E | NT5E 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.